VIDEO: Novel dry eye treatment safe, well-tolerated through phase 3

ByWalter O. Whitley, OD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Pooled analysis showed that KPI-121 0.25% from Kala Pharmaceuticals, a nanoparticle suspension of loteprednol etabonate with proprietary mucus-penetrating particle technology for dry eye treatment, was safe and well-tolerated.

In this video, Walt Whitley, OD, MBA, FAAO, speaks at the virtual American Academy of Optometry virtual meeting about the phase 2 safety data and the ongoing phase 3 evaluation for both symptoms and signs of dry eye. Since filming, the FDA approved KPI-121 (Eysuvis) for short-term dry eye treatment.